ORION CORPORATION PRESS RELEASE 30 April 2018 at 12.15 p.m.
Orion has completed the sale of Orion Diagnostica business division
Orion Corporation has completed the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division) to an investment fund managed by Axcel Management A/S.
The Closing of the transaction took place today, 30 April 2018, so the ownership of Orion Diagnostica has been transferred to the buyer.
Orion published a stock exchange release about the transaction on 21 April 2018. (https://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2018/orion-to-sell-its-orion-diagnostica-division---due-to-the-transaction-orion-updates-its-outlook/)
Contact person:
Jari Karlson, CFO, Orion Corporation
tel. +358 (0)50 966 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi/en (http://www.orion.fi)
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's adjusted net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire
